XBIvsPSCHETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) and Invesco S&P SmallCap Health Care ETF (PSCH) belong to the same industry segment: US Health Care. XBI's top 2 sector exposures are Healthcare and Finance. In contrast, PSCH's top sector exposures are Healthcare. XBI is more expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.29% for PSCH. XBI is up 34.48% year-to-date (YTD) with +$925M in YTD flows. PSCH performs worse with 23.3% YTD performance, and +$7M in YTD flows. Run a side-by-side ETF comparison of XBI and PSCH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs PSCH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/04/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI PSCH | +7.89%+0.51% | +22.96%+17.92% | +34.48%+23.30% | +76.10%+31.20% | +107.25%+31.27% | +23.60%-13.95% |
| Flows | XBI PSCH | +$725M+$14M | +$1.19B+$25M | +$925M+$7M | +$1.79B+$2M | +$130M-$110M | +$1.57B-$207M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI PSCH | +30.41%+16.48% | +27.90%+19.64% | +28.23%+21.90% | +32.90%+22.87% |
| Max drawdown | XBI PSCH | -10.46%-3.14% | -10.46%-15.36% | -32.94%-22.80% | -53.28%-45.76% |
| Max drawdown duration | XBI PSCH | 40d16d | 40d168d | 331d488d | 1622d1761d |
Trading data
XBI | PSCH | |
Last sale 9/4/2026 at 1:30 PM | $163.81 | $54.36 |
| Previous close 09/03/2026 | $164.38 | $54.75 |
| Consolidated volume 09/03/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | PSCH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/4/2026 at 1:30 PM
Live
Closed
XBI | PSCH | |
|---|---|---|
| Last price | $163.81 | $54.36 |
| 1D performance | -0.35% | -0.71% |
| AuM | $11.43 B | $183.73 M |
| E/R | 0.35% | 0.29% |
Characteristics
XBI | PSCH | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | Invesco |
| Benchmark | S&P Biotechnology Select Industry Index | S&P SmallCap 600 Capped Health Care Index |
| N° of holdings | 149 | 69 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | April 7, 2010 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.3%
Other
4.7%
PSCH
USA
95.04%
Other
4.96%
Sectors
XBI
Healthcare
99.41%
Other
0.59%
PSCH
Healthcare
100%
Other
0%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
20.29%
PSCH
Total weight of top 15 holdings out of 15
48.1%
Top 15 holdings
Data as of July 31, 2026
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
PSCH
Glaukos Corp.
4.96%
Corcept Therapeutics, Inc.
4.64%
Alkermes Plc
4.21%
Protagonist Therapeutics, Inc.
4.20%
TG Therapeutics, Inc.
3.68%
PTC Therapeutics, Inc.
3.23%
Liquidia Corp.
3.19%
Teleflex, Inc.
3.11%
Ligand Pharmaceuticals, Inc.
3.01%
Indivior Pharmaceuticals, Inc.
2.55%
Merit Medical Systems, Inc.
2.52%
RadNet, Inc.
2.34%
Veracyte, Inc.
2.32%
ICU Medical, Inc.
2.17%
Concentra Group Holdings Parent, Inc.
1.96%
Frequently asked questions about XBI and PSCH
How have the XBI and PSCH ETFs performed in 2026?
As of September 4, 2026, XBI is up 34.48% year-to-date (YTD), while PSCH has returned 23.3%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or PSCH?
Year-to-date, the XBI ETF saw +$925M in flows, compared to +$7M for PSCH.
Which ETF is more volatile: XBI or PSCH?
Over the past year, XBI had a volatility of 27.9%, while PSCH experienced 19.64%.
Which ETF is bigger: XBI or PSCH?
As of September 4, 2026, XBI holds $11.43 B in assets under management (AUM), while PSCH manages $183.73 M.
What sectors do the XBI and PSCH ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, PSCH focuses on Healthcare.
What are the top holdings of the XBI ETF and PSCH ETF?
XBI top holdings include Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc.. PSCH holds in its top three: Glaukos Corp., Corcept Therapeutics, Inc. and Alkermes Plc.
Which ETF is more diversified: XBI or PSCH?
XBI holds 151 securities with 20.29% of its assets in the top 15. PSCH has 69 securities and a top 15 weight of 48.1%.
Advertisement
Latest news about XBI & PSCH
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
